Sakar Healthcare Limited (NSE:SAKAR)
388.20
-20.40 (-4.99%)
Jan 23, 2026, 3:29 PM IST
Sakar Healthcare Revenue
Sakar Healthcare had revenue of 575.60M INR in the quarter ending September 30, 2025, with 34.56% growth. This brings the company's revenue in the last twelve months to 2.04B, up 23.91% year-over-year. In the fiscal year ending March 31, 2025, Sakar Healthcare had annual revenue of 1.78B with 15.53% growth.
Revenue (ttm)
2.04B
Revenue Growth
+23.91%
P/S Ratio
4.22
Revenue / Employee
5.98M
Employees
342
Market Cap
8.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.78B | 239.40M | 15.53% |
| Mar 31, 2024 | 1.54B | 199.75M | 14.89% |
| Mar 31, 2023 | 1.34B | 50.74M | 3.93% |
| Mar 31, 2022 | 1.29B | 338.06M | 35.47% |
| Mar 31, 2021 | 953.12M | 113.97M | 13.58% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.25B |
| Nectar Lifesciences | 16.70B |
| Solara Active Pharma Sciences | 12.06B |
| Windlas Biotech | 8.30B |
| Orchid Pharma | 8.21B |
| Ind-Swift Laboratories | 5.72B |
| Sigachi Industries | 5.09B |
| Beta Drugs | 3.86B |
Sakar Healthcare News
- 5 weeks ago - Sakar Healthcare gets EMA approval to manufacture Imatinib for Accord’s European market - Business Upturn
- 2 months ago - Sakar Healthcare shares rise over 2.5% after securing nine new oncology product approvals across global markets - Business Upturn
- 2 months ago - Sakar Healthcare receives nine new marketing authorisations for Oncology products in EU and emerging markets - Business Upturn